oPTion-DDR: A randomized phase III trial investigating Platinum and Taxane chemotherapy in metastatic castration resistant prostate cancer patients with alterations in DNA Damage Response (DDR) genes
oPTion-DDR: A randomized phase III trial investigating Platinum and Taxane chemotherapy in metastatic castration resistant prostate cancer patients with alterations in DNA Damage Response (DDR) genes
oPTion-DDR：一项随机 III 期试验，研究铂类和紫杉烷化疗对 DNA 损伤反应 (DDR) 基因改变的转移性去势抵抗性前列腺癌患者的影响
批准号：
477946
负责人：
Kolinsky Michael
金额：
$133.2万
依托单位：
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2023
资助国家：
加拿大
项目状态：
未结题
起止时间：
2023-03-01 至 2029-06-01
中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
In 2020, 23,300 people were diagnosed with prostate cancer (PCa) in Canada. Despite medical and surgical interventions, 1 in 4 will die from the disease. Approximately 25% of advanced PCa patients have alterations in genes that normally repair damage to o
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金
